OPKO Health and Entera Bio present new data at ENDO 2025 annual meeting.

OPKO Health and Entera Bio announced new in vivo data for oral OPK-88006, a dual agonist GLP-1/glucagon peptide for obesity and metabolic disorders. The data will be presented at the ENDO 2025 annual meeting. Oral OPK-88006 is a tablet treatment being developed through a collaboration and license agreement between the two companies.

OPKO Health (NASDAQ: OPK) and Entera Bio announced the selection of their abstract for oral presentation at the ENDO 2025 annual meeting. The abstract details new in vivo data for OPK-88006, a novel dual GLP-1/glucagon peptide treatment for obesity and metabolic disorders [1]. This oral treatment, being developed as a once-daily tablet and a weekly subcutaneous injection, combines OPKO's long-acting oxyntomodulin analog with Entera's N-Tab™ technology.

The presentation, scheduled for July 13, 2025, will showcase the pharmacologic and pharmacokinetic data of OPK-88006. The companies plan to file an Investigational New Drug (IND) application with the FDA later in 2025, followed by Phase 1 clinical studies. This marks a significant milestone in the development of OPK-88006, which aims to address the growing market for obesity therapeutics [2].

The oral delivery format of OPK-88006 represents a potential advantage over current market-leading injectable GLP-1 agonists. An effective oral alternative could capture substantial market share if it demonstrates comparable efficacy with improved convenience and tolerability. The dual-mechanism approach of OPK-88006, which includes glucagon activation, could enhance metabolic benefits beyond what GLP-1 alone provides [1].

The upcoming presentation at ENDO 2025 will provide crucial insights into the pharmacokinetic data of OPK-88006, which is essential for further development. However, investors should recognize that this program remains in preclinical stages and requires several years of clinical development before potential commercialization [2].

References:
[1] https://www.stocktitan.net/news/OPK/opko-health-and-entera-bio-abstract-for-first-in-class-dual-glp-1-buci39mc8xnv.html
[2] https://www.globenewswire.com/news-release/2025/06/25/3105023/0/en/OPKO-Health-and-Entera-Bio-Abstract-for-First-in-Class-Dual-GLP-1-Glucagon-Tablet-Candidate-for-Patients-with-Obesity-and-Metabolic-Disorders-Selected-for-Presentation-at-the-ENDO-.html